Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Journal of Thrombosis and Haemostasis : JTH|October 17, 2019
Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)Robert Klamroth, Clemens Feistritzer, Ute Friedrich, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 25, 2021
Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia AAndreas Tiede, Kingsley Hampton, Victor Jiménez-Yuste, et al.
Blood Advances|February 12, 2026
A Revised Classification of FVIII Concentrates: Rationale and Novel MetricsCédric Rjr Hermans, Pratima Chowdary, Barbara A Konkle, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|August 27, 2025
Corrigendum: Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia APratima Chowdary, Liane Khoo, Michael Wang, et al.
Therapeutic Drug Monitoring|March 31, 2022
Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic ModelsDavid W Uster, Pratima Chowdary, Anne Riddell, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 4, 2025
Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia APratima Chowdary, Liane Khoo, Michael Wang, et al.
Kidney International|March 22, 2013
Hemostasis in patients with acute kidney injury secondary to acute liver failureBanwari Agarwal, Alex Gatt, Anne Riddell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 20, 2023
Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GPJohannes Oldenburg, Gary Benson, Pratima Chowdary, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 9, 2018
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b dataHermann Eichler, Pantep Angchaisuksiri, Kaan Kavakli, et al.
Pageof 13